GROUP FINANCIAL AND OPERATING HIGHLIGHTS
27% increase in Group revenue of which 16% was contributed by Al Noor
Strong performance in Switzerland with revenue up 5% and underlying EBITDA up 7%
Good organic growth in Southern Africa supported by infrastructure investment
Middle East business impacted by new insurance co-payment requirement, doctor vacancies and delayed facility openings
Integration of Al Noor on track to deliver AED75m of annualised synergies
Underlying EBITDA up 11% to £220m
Operating profit up 10% to £169m
Underlying earnings per share decreased by 26% to 12.8 pence, largely impacted by the shares issued to acquire and adverse operating performance of Al Noor
Cash flow conversion 95% of underlying EBITDA
Interim dividend per ordinary share up to 3.20 pence
Continued investments to improve patient experience and clinical quality
